Reduced L-selectin (CD62L Low) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine

Abstract

Reduced expression of CD62L can identify tumor-specific T cells in lymph nodes draining murine tumors. Here, we examined whether this strategy could isolate tumor-specific T cells from vaccinated patients. Tumor vaccine-draining lymph node (TVDLN) T cells of seven patients were separated into populations with reduced (CD62L Low) or high levels of CD62L (CD62L High). Effector T cells generated from CD62L Low cells maintained or enriched the autologous tumor-specific type 1 cytokine response compared to unseparated TVDLN T cells in four of four patients showing tumor-specific cytokine secretion. Interestingly, effector T cells generated from CD62L Low or CD62L High TVDLN were polarized towards a dominant type 1 or type 2 cytokine profile, respectively. For CD62L Low T cells the type 1 cytokine profile appeared determined prior to culture. Since a tumor-specific type 1 cytokine profile appears critical for mediating anti-tumor activity in vivo, this approach might be used to isolate T cells for adoptive immunotherapy.